Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
Autoimmune Encephalitis
About this trial
This is an interventional treatment trial for Autoimmune Encephalitis focused on measuring autoimmune encephalitis, minocycline
Eligibility Criteria
Inclusion Criteria: Diagnosis of definite autoimmune encephalitis(Graus et al 2016.) Age ≥ 18 years Acute or subacute onset (rapid progression of less than 3 months) Reasonable exclusion of alternative causes Written informed consent Exclusion Criteria: Known allergy to tetracycline antibiotics. Pregnant women. Uncontrolled serious concomitant illness. Known chronic kidney disease stages 3b-5. Moderate liver disease (see Child-Pugh for Classification of Severity of Liver Disease). history of cognitive impairment
Sites / Locations
- Xijing HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Experimental: Treatment group
Control group
Drug: Minocyclin 200 mg oral minocycline for a total of 30 days
first/second-line drugs for autoimmune encephalitis